Multiple Sclerosis: Neurologist and Payer Receptivity to Gilenya, Tysabri and Late-Stage Emerging Agents that Could Reshape the Treatment Algorithm - On Demand

Based on our U.S. Physician & Payer Forum report Physician and Payer Attitudes Towards Gilenya and Emerging Oral and Parenteral Disease-Modifying Therapies in the U.S. Multiple Sclerosis Market, Decision Resources is offering this exclusive webinar.

Date & Time
Recorded live on Wednesday, December 14, 2011
10 a.m. ET, 4 p.m. CET

Click here to view the invite.

To learn how you can access the recorded playback of this live event, please fill out the following form and a representitive will contact you:

*First Name: *Last Name:  Title: *Company:  Phone: *Email Address:  Comments: *Agreement: No Yes I have read and agree to abide by the Decision Resources Terms of Use and Privacy Policy. *Required